Stanford University
Showing 601-610 of 2,431 Results
-
Peter Fitzgerald, MD, PhD
Professor (Research) of Medicine (Cardiovascular), Emeritus
BioDr. Peter Fitzgerald is the Director of the Center for Cardiovascular Technology and the Cardiovascular Core Analysis Laboratory (CCAL) at Stanford University School of Medicine. He is an interventional cardiologist and holds a PhD in engineering. He is a professor in both the Department of Medicine and the Department of Engineering (by courtesy) at Stanford.
Dr. Fitzgerald has led or participated in more than 175 clinical trials, has published more than 550 manuscripts and book chapters, and lectures worldwide. Over the past two decades, he has trained more than 150 postdoctoral researchers in engineering and medicine. Most recently, Dr. Fitzgerald completed two years of study toward a master’s degree focused on machine learning and agentic principles supporting AI.
Dr. Fitzgerald has been a principal founder of 24 medical startups in the San Francisco Bay Area and has transitioned 17 of them to large medical device companies. He serves on several boards of directors and advises dozens of medical device startups, as well as multinational healthcare companies, on the design and development of new diagnostic and therapeutic devices in the cardiovascular arena. In 2001, Dr. Fitzgerald was part of the founding team of LVP Capital, a venture firm focused on medical device and biotechnology startups in San Francisco. In 2010, he co-founded Triventures, an early-stage medical technology fund with offices in Palo Alto and Tel Aviv. -
Annesa Flentje
Professor (Research) of Medicine (Stanford Prevention Research Center)
BioAnnesa Flentje, PhD, is a Professor at Stanford University in the Stanford Prevention Research Center, Department of Medicine, School of Medicine. Dr. Flentje is a clinical psychologist who uses multiple methods to understand the impacts of stress and coping on human health and disease. Her research has investigated how stress directly impacts health outcomes and how these processes are mediated through both behaviors (e.g., substance use and coping) and molecular mechanisms (e.g., epigenetics and transcriptional regulation). Dr. Flentje has developed cognitive behavioral interventions to reduce stress, and identified these as a mechanism to alter immune pathways in gene expression. Dr. Flentje is currently leading a large comparative effectiveness study of two interventions for posttraumatic stress symptoms among LGBTQIA+ populations in California. Dr. Flentje has developed and led nationwide mentoring initiatives to support health research of understudied populations and translational research to improve health. Dr. Flentje is Co-Director of The PRIDE Study (pridestudy.org), a national longitudinal cohort study of LGBTQIA+ individuals within the United States that has enrolled over 30,000 participants and is approaching 10 years of data collection.
-
James Ford
Professor of Medicine (Oncology) of Genetics and, by courtesy, of Pediatrics
Current Research and Scholarly InterestsMammalian DNA repair and DNA damage inducible responses; p53 tumor suppressor gene; transcription in nucleotide excision repair and mutagenesis; genetic determinants of cancer cell sensitivity to DNA damage; genetics of inherited cancer susceptibility syndromes and human GI malignancies; clinical cancer genetics of BRCA1 and BRCA2 breast cancer and mismatch repair deficient colon cancer.
